
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinsons disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn is BrainStorms proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinsons, Huntingtons, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating...
Stem cell therapy,drug development,neurodegenerative diseases,and als
Brainstorm cell therapeutics operates in the Biotechnology research industry.
Brainstorm cell therapeutics's revenue is 1m - 10m
Brainstorm cell therapeutics has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.